Alcon heads into today's earnings call having delivered a Q1 beat on the bottom line — and a modest guidance raise — while the stock's recent slide had signalled growing caution in the weeks beforehand.
The pre-print positioning told a clear story of rising hedging costs rather than aggressive short-side conviction. Borrow costs more than doubled over the past month to 1.42%, after sitting quietly in the 0.65%–0.70% range for most of April. That spike was notable even as short interest remained negligible — close to zero percent of free float — and the ORTEX short score of 30.7 placed Alcon near the bottom third of the universe for short-selling pressure. Availability in the lending pool remained ample. The cost move looked less like a crowding trade and more like pre-event demand for borrows from hedgers seeking protection into the print.
The price action added to the cautious tone. Alcon had given back roughly 3.5% over the prior month to CHF 58.22, unwinding more than half of its earlier gains, while peers including GEHC fell sharply — down 13.4% on the week — providing some regional and sector drag. Sonova and were flatter over the same period, suggesting the selling in medtech was concentrated in specific names rather than a broad rotation.
The debate around Alcon heading into Q1 centred on whether new product momentum could overcome macro headwinds and a stronger Swiss franc. The bull case rested on the Unity surgical platform and the Tryptyr dry-eye franchise — both flagged explicitly by management as growth drivers in last night's release. On the bear side, currency pressure and a soft procedure volume environment had kept consensus cautious. Forward EPS growth sits in the 92nd percentile of the universe, pointing to strong earnings trajectory expectations, while the dividend score ranks in the top 7% — both consistent with a quality-growth investment case. Valuation has compressed: the PE multiple has shed more than one full turn over the past month to around 20.5x, reflecting the stock's retreat from its February highs near CHF 83.
The print itself delivered Q1 adjusted EPS of $0.85, beating the $0.81 estimate, though revenue of $2.685 billion came in fractionally below the $2.712 billion consensus. Alcon narrowed the full-year adjusted EPS range to $3.38–$3.47 from $3.35–$3.44, while reaffirming sales guidance of $10.835–$11.041 billion against a Street estimate running slightly above that band. The results test whether the earnings beat and guidance nudge are enough to lift the stock back toward the levels at which the CFO and other insiders were selling in late February — or whether the revenue miss and the in-line-to-below sales guidance keep the shares range-bound at current levels.
See the live data behind this article on ORTEX.
Open ALC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
